A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
Public ClinicalTrials.gov record NCT01280552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM). ICT-107 is an immunotherapy in which the patient's immune response will be stimulated to kill the tumor cells. Patients must be newly diagnosed with GBM and not yet received chemoradiation. Some of the patient's white blood cells (WBC) will be removed and cultured in a laboratory with purified antigens, similar to those on GBM cells. The patient's own WBC/DC that have been exposed to the tumor antigens will then be given back to the patient as a vaccine over several months. The goal is for the ICT-107 vaccine to stimulate the patient's immune response to kill the remaining GBM tumor cells after surgery and chemotherapy.
Study identification
- NCT ID
- NCT01280552
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2011 (Type not available)
- Primary completion
- Dec 2013 (Actual)
- Completion
- Dec 2015 (Actual)
- Last update posted
- Mar 20, 2017
2011 – 2015
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birbingham School of Medicine | South Birmingham | Alabama | 35294 | — |
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Jewish Hospital Medical Center | Louisville | Kentucky | 40245 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21287 | — |
| Massachusetss General Hospital | Boston | Massachusetts | 02114 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| New Jersey Neuroscience Institute | Edison | New Jersey | 08818 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| The Long Island Brain Tumor Center at Neurological Surgery, PC | Great Neck | New York | 11021 | — |
| NYU Clinical Cancer Center | New York | New York | 10016 | — |
| Weil Cornell Medical College | New York | New York | 10065 | — |
| Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
| Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center | Cleveland | Ohio | 44195 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Sammons Cancer Center (Baylor) | Dallas | Texas | 75246 | — |
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01280552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01280552 live on ClinicalTrials.gov.